In the quarter, growth in cancer drugs moderated generic competition and pricing pressures in respiratory and diabetes markets. We expect this trend to continue, but the gains in cancer drugs should ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback